Fataler Verlauf nach erfolgreicher pulmonaler Endarteriektomie – der seltene Fall

Zusammenfassung

Wir berichten über eine 43-jährige Frau, die sich nach stattgehabten rezidivierenden Lungenarterienembolien mit Entwicklung einer chronischen thromboembolischen pulmonalen Hypertonie einer primär erfolgreichen pulmonalen Endarteriektomie unterzog. Zwei Jahre später, nach stattgehabter SARS-CoV-2-Infektion und trotz konsequent eingenommener oraler Antikoagulation, wurde die Patientin erneut vorstellig mit klinischen Zeichen einer Lungenarterienembolie, die sich bildgebend als fulminante Lungenarterienembolie darstellte. Trotz medikamentöser Fibrinolysetherapie und dem Versuch einer interventionellen Thrombusaspiration gelang es nicht, die große Embolielast zu beherrschen, sodass die Patientin bedauerlicherweise verstarb.

Abstract

We report a case of a 43-year-old woman who suffered from recurrent pulmonary embolism leading to chronic thromboembolic pulmonary hypertension. Pulmonary endarterectomy was performed with good result. However, two years later, after a SARS-CoV2 infection and despite oral anticoagulation therapy, the patient presented with clinical symptoms of pulmonary embolism, which was confirmed by computed tomography as an extensive pulmonary embolism. Despite fibrinolysis therapy and the attempt of interventional thrombus aspiration, the patient died due to non-manageable embolism load.

Schlüsselwörter

Lungenarterienembolie - pulmonale Hypertonie - pulmonale Enderteriektomie - SARS-CoV-2

Keywords

pulmonary embolism - pulmonary hypertension - pulmonary endarterectomy - SARS-CoV-2

Publikationsverlauf

Eingereicht: 16. Juni 2023

Angenommen nach Revision: 28. August 2023

Artikel online veröffentlicht:
19. Oktober 2023

• Literatur

• 1 Iba T, Levy JH, Connors JM. et al. The unique characteristics of COVID-19 coagulopathy. Crit Care 2020; 24: 360 DOI: 10.1186/s13054-020-03077-0. (PMID: 32552865)
• 2 Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost 2020; 26: 1076029620938149 DOI: 10.1177/1076029620938149. (PMID: 32677459)
• 3 Manolis AS, Manolis TA, Manolis AA. et al. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. J Cardiovasc Pharmacol Ther 2021; 26: 12-24 DOI: 10.1177/1074248420958973. (PMID: 32924567)
• 4 Siddiqui SN, Jayasekhar R, Tshering S. et al. A unique tale of COVID-19 induced concomitant overt disseminated intravascular coagulation and acute bilateral pulmonary embolism. Int J Infect Dis 2021; 104: 568-571 DOI: 10.1016/j.ijid.2021.01.040. (PMID: 33486013)
• 5 Ali EW, Ibrahim IK. Multi-factorial Mechanism Behind COVID-19 Related Thrombosis. Med Arch 2022; 76: 62-65 DOI: 10.5455/medarh.2022.76.62-65. (PMID: 35422572)
• 6 Faccioli E, Verzeletti V, Perazzolo Marra M. et al. Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review of the Most Updated Literature. J Clin Med 2022; 11: 6976
• 7 Konstantinides SV, Meyer G, Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). The European respiratory journal 2019; 54: 1901647 DOI: 10.1183/13993003.01647-2019.
• 8 Khairani CD, Bejjani A, Piazza G. et al. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J Am Coll Cardiol 2023; 81: 16-30
• 9 Wu X, Cao S, Yu B. et al. Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 2022; 33: 389-401
• 10 Bunclark K, Ansaripour A, Sheares K. et al. Response to letter to the Editor: Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2020; 18: 756-757
• 11 Humbert M, Simonneau G, Pittrow D. et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2022; 41: 716-721 DOI: 10.1016/j.healun.2022.02.002. (PMID: 35305871)
• 12 Dubs L, Ulrich S, Lichtblau M. et al. Pulmonale Endarteriektomie und Behandlung der chronisch thromboembolischen pulmonalen Hypertonie. Praxis 2023; 112 (1): 28-35
• 13 Guth S, D’Armini AM, Delcroix M. et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res 2021; 7: 00850-2020 DOI: 10.1183/23120541.00850-2020. (PMID: 34409094)
• 14 Simonneau G, Dorfmuller P, Guignabert C. et al. Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Ann Cardiothorac Surg 2022; 11: 106-119 DOI: 10.21037/acs-2021-pte-10. (PMID: 35433354)
• 15 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European heart journal 2022; 43: 3618-3731 DOI: 10.1093/eurheartj/ehac237. (PMID: 36017548)